Business · 02/10/2024Updated: 10/17/2026 · 1 min read
FDA Announces Public Meeting of Endocrinologic and Metabolic Drugs Advisory Committee for Sotagliflozin New Drug Application
Summary
The US Food and Drug Administration (FDA) is hosting a public meeting of its Endocrinologic and Metabolic Drugs Advisory Committee to discuss a new drug application for Sotagliflozin, and is seeking public comments on the proposal.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →